The Canadian government is stepping into bold new territory with the development of a groundbreaking mRNA-based aerosol vaccine known as “AeroVax.” Designed to address vaccine hesitancy, AeroVax aims to simplify immunization by eliminating needles entirely—instead, it’s inhaled as a fine mist.
Unlike traditional vaccines administered by injection, AeroVax is delivered through the air and absorbed through the lungs, offering a needle-free alternative that could transform public health strategies.
Developed by researchers at McMaster University—backed by funding from the Bill and Melinda Gates Foundation—the AeroVax project has now received an $8 million boost from the Canadian Institutes of Health Research (CIHR) as it moves into its next phase of clinical testing.
Scientists behind the experimental mRNA-based Covid “vaccine” known as Serova are promoting a new approach to immunization—delivering it as a simple nasal spray.
The implications of aerosol-based vaccines go far beyond individual use. With technology like AeroVax, the potential exists to disperse the vaccine through the atmosphere, enabling mass immunization on a scale never seen before.
Such a method could theoretically “vaccinate” entire cities or regions simultaneously—without the need for personal appointments, needles, or even individual awareness. In this scenario, public consent could be bypassed entirely, raising pressing questions about autonomy, ethics, and transparency in public health.
Concerns surrounding inhaled mRNA “vaccines” have been echoed by numerous experts as development continues to accelerate.
“When you put the pieces of the puzzle together, a disturbing picture emerges,” cautioned Dr. Joseph Mercola in 2023, when the technology first began gaining traction.
Slay News was among the first to spotlight the emerging trend, reporting on the launch of Phase 1 trials for inhaled Covid vaccines that year.
Initial studies in mice produced results that had researchers proclaiming the potential for a game-changing breakthrough—suggesting this innovative delivery method could completely redefine how vaccines are administered in the future.
The first human trials of the experimental vaccine saw 36 volunteers take part in the groundbreaking study.
Researchers reported that the Phase 1 trials were completed without any serious side effects, marking a promising early step in the development of this new delivery method.
Building on the momentum of the initial success, researchers are now fast-tracking into Phase 2 trials.
They’re actively seeking 350 volunteers to participate in the next stage—a rigorous, randomized, double-blind study designed to further test the safety and effectiveness of the inhaled vaccine.
In the upcoming trial, 75 percent of participants will receive the actual vaccine candidate, while the remaining volunteers will be given a placebo.
The two inhaled Covid vaccine prototypes—named Tri:ChAd and Tri:HuAd—were first developed in 2021 and represent a new frontier in respiratory immunization.
Much like traditional mRNA shots, both versions of the AeroVax use a form of the Covid virus’s spike protein to trigger an immune response, but deliver it through a completely needle-free, airborne method.
Both versions of the AeroVax vaccine—Tri:ChAd and Tri:HuAd—were developed using HEK293 fetal cell lines, a common cell culture originally derived from kidney tissue of an aborted fetus in the Netherlands during the 1970s.
According to the full research abstract, “Tri:HuAd was packaged and rescued in HEK293 cells through a two-plasmid co-transfection system.”
Despite the ethical debate surrounding the use of fetal cell lines, McMaster University reports that pre-clinical trials in animals have already delivered striking results—showing that the inhaled aerosol vaccine generates a significantly stronger immune response than traditional injections.
McMaster University attributes the enhanced effectiveness of the inhaled vaccine to its ability to directly target the upper respiratory tract—the primary entry point for airborne viruses.
At the same time, momentum is building in the U.S., where the FDA has granted Fast Track Designation to a new self-amplifying “replicon” mRNA vaccine aimed at combating the H5N1 bird flu.
The vaccine, ARCT-2304, is being developed by Arcturus Therapeutics—a Bill Gates–funded biotech firm focused on cutting-edge mRNA technology. Notably, one of the company’s senior advisors, Dr. Peter A. Patriarca, is a former CDC and FDA official who also serves as an advisor to the Gates Foundation, highlighting the deep interconnections shaping the future of vaccine innovation.
As previously reported by Slay News, the new “self-amplifying” or “replicon” mRNA vaccines are designed to do more than just deliver genetic instructions—they actually replicate inside the body, continuously producing more mRNA after entering cells.
Dubbed “replicon” vaccines for this very reason, the technology represents a major leap in how vaccines function—but it’s also sparked intense global backlash. Experts and citizens alike have voiced serious concerns over the implications of a vaccine that keeps reproducing within the human body.
Still, despite the growing outcry, federal health agencies are pushing full steam ahead with the development of these next-gen injections, accelerating trials and approvals in an effort to bring them to market.
No comments:
Post a Comment